Featured Suppliers:
Sponsored Links
Cell Genesys Incorporated
News and Blogs
Total : 5 View more »
Transformative Times for BioSante Pharmaceuticals -- Seeking Alpha
seekingalpha.com | Oct 21, 2009
"The last 75 days have been transformative for BioSante," Bill Milling, Sr. Dir Operations for BioSante Pharmaceuticals, Inc. (BPAX) told BioMedReports. Yesterday, the company announced positive safety data in its ongoing LibiGel Phase III clinical development program.
http://seekingalpha.com/article/167782-transformative-times-for-biosante-pharmaceuticals?source=feed
BioSante Pharmaceuticals and Cell Genesys Announce Completion of Merger
www.pharmiweb.com
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=8499
BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. Announce September 30, 2009 Special Stockholders Meetings to Approve Merger
www.biospace.com | Sep 3, 2009
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the
http://www.biospace.com/news_story.aspx?StoryID=154898&full=1
BioSante completes Cell Genesys buyout | R&D Mag
www.rdmag.com | Oct 14, 2009
BioSante-Cell Genesys to focus on developing therapy to treat female sexual dysfunction
http://www.rdmag.com/News/FeedsAP/2009/10/life-sciences-biosante-completes-cell-genesys-buyout/
News from Zibb.com
Total : 29 View more »
Cell Genesys Inc (CEGE) Corporate Event Announcement Notice - Zibb.com
Oct 28, 2009 (Wall Street Horizon via COMTEX) --
Cell Genesys Inc (CEGE)
Expected next earnings release: Announcement date: 11/5/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market
Companies: Cell Genesys, Inc. (CEGE)
Cell Genesys Inc (CEGE) Corporate Event Announcement Notice - Zibb.com
Oct 29, 2009 (Wall Street Horizon via COMTEX) --
Cell Genesys Inc (CEGE)
Expected next earnings release: Announcement date: 11/5/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market
Companies: Cell Genesys, Inc. (CEGE)
Cell Genesys Inc (CEGE) Corporate Event Announcement Notice - Zibb.com
Oct 21, 2009 (Wall Street Horizon via COMTEX) --
Cell Genesys Inc (CEGE)
Expected next earnings release: Announcement date: 11/5/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market
Companies: Cell Genesys, Inc. (CEGE)
BioSante Pharmaceuticals and Cell Genesys Finalize Merger - Zibb.com
Oct 21, 2009 (Close-Up Media via COMTEX) --
BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. has announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.
In a release, the group noted that BioSante intends to focus primarily on LibiGel, BioSante's testosterone gel in Phase III clinical development under a U.S. Food and Drug Administration (FDA) agreed Special Protocol Assessment (SPA) for the treatment of female sexual dysfunction (FSD). BioSante also intends to seek future development opportunities for GVAX Immunotherapies including combinations with BioVant, BioSante's vaccine adjuvant, and possible external collaborations, and also will seek to outlicense other former Cell Genesys technologies. In addition, BioSante now owns a 16 percent equity ownership position in Ceregene, Inc., a former subsidiary of Cell Genesys which is developing gene therapies for neurodegenerative disorders.
"Closing the merger today is a very exciting development for BioSante. We now have accomplished our objective of having enough cash on hand to complete the LibiGel clinical development program to and through submission of a new drug application (NDA) in the first half of 2011," said Stephen M. Simes, president and CEO of BioSante. "The merger follows our successful registered direct financing closed on August 13, and our recent announcement of continued safety of LibiGel in our Phase III clinical studies. We now will accelerate completion of the LibiGel clinical development program to be in a position to submit the NDA in a timely fashion. We also will work to maximize the value of our newly acquired GVAX immunotherapies."
"The successful closing of our merger with BioSante provides an impressive array of opportunities to create value from the assets of the combined company," said Stephen A. Sherwin, M.D., the former chairman and CEO of Cell Genesys, and as a result of the merger, a new director of BioSante. "I am very pleased to have the opportunity to serve as a director of BioSante and look forward to working with the BioSante team."
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.
((Comments on this story may be sent to health@closeupmedia.com))
Tags: ceo clinical contraception equity fashion fda health menopause merger pharmaceuticals president products technology vaccine
Companies: BioSante Pharmaceuticals, Inc. (BPAX), Cell Genesys, Inc. (CEGE), Genesys (GNSYY)
Web Sites
Total : 97 View more »
Cell Genesys, Inc.
500 FORBES BOULEVARD SOUTH SAN FRANCISCO CALIFORNIA 94080 T 650.266.3000 F 650.266.
Cell Genesys
Hane Chow Inc. 236 2nd Street, Oakland, CA 94607 / 510 302 0590 t / email: No Javascript! Studio / Work Work Annual Reports / Branding & Collateral / Packaging / Web Development Anza Therapeutics / Blue Bee Printing / Cell Genesys / CPI International / Depomed / Exelixis / Farmhouse Foods /
Cell Genesys | Geron
We initially granted a non-exclusive license to Genetic Therapy, Inc. (GTI), a subsidiary of Novartis AG, to use our telomerase promoter technology to develop an oncolytic virus product. Subsequently, GTI's oncolytic virus business including our license to GTI was acquired by Cell Genesys Inc.
Maxygen | About Maxygen | Leadership
Corporate Leadership Russell J. Howard, Ph.D. Chief Executive Officer Dr. Howard has served as the Companyâ s Chief Executive Officer and as a director since June 1998. Dr. Howard was elected the Companyâ s President and Chief Operating Officer in May 1997.
Web Sites
powered by 
Total : 80 View more »
ASGT Annual Meeting
www.asgt.org
Cell Genesys, Incorporated Foster City, California Kenneth Cornetta, MD Indiana University Indianapolis, Indiana Maria A. Croyle, PhD The University of Texas at Austin
American Society of Gene Therapy | 8th Annual Meeting
www.asgt.org
Cell Genesys Incorporated South San Francisco, California. Adriana Heguy, PhD Weill Medical College of Cornell University New York, New York. Richard Heller, PhD
Geoffrey Meacham, The Best Analysts - Stock Pickers 2006 - Forbes.com
www.forbes.com
****Four-star stock pickers are in the top one-third of analysts in the StarMine database. ***** - Five-star stock pickers are in the top ten percent of analysts in the StarMine database
November 2004
www.dartmouth.edu
Cell Genesys, Incorporated "CG1940 and CG8711 vs Docetaxel" Fesen, R. - Physics and Astronomy. Jet Propulsion Laboratory "Infrared Study of Supernova Ejecta and Dust"